Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer
Authors' conclusion
Levels of AMH were lower after multiple RAI doses, especially after a cumulative RAI dose above 200 mCi. More studies are needed to clarify the impact of RAI on fertility considering its cumulative activity and treatment strategy.
Study context
- Population
- Women with pediatric differentiated thyroid cancer (DTC) treated with radioiodine (RAI) at age ≤19 years; mean age 25.1 years (12.4–50.8) at anti-Müllerian hormone (AMH) measurement; follow-up 11.8 ± 8.4 years
- Participants
- 47 women
- Exposure
- Multiple vs single RAI doses
- Multiple RAI dosesn = 16
- Outcome
- Serum AMH level
Main finding
As reported in the abstract
Serum AMH
P = 0.01
- Mean AMH, all patients
- 2.49 ng/mL (0.01-7.81)
Observational data: associations, not effects.
Further findings
Serum AMH by cumulative RAI (<200 mCi vs more) · higher with <200 mCi
P = 0.02
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| AMH below age reference range, multiplevs single RAI doses (similar cumulative RAI)Age-adjusted | 5.9 (1.55–52.2) | P = 0.014 | |
| 0.050.21520Hazard ratio (log scale) |
Original publication
Serum anti-Müllerian hormone is lower in patients with multiple radioiodine dose for treatment of pediatric thyroid cancer. Eur Thyroid J. Published 7 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →